Cargando…
Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure()
The proteasome inhibitor Bortezomib is used to treat multiple myeloma (MM). Bortezomib inhibits protein degradation by inactivating proteasomes' active-sites. MM cells are exquisitely sensitive to Bortezomib – exhibiting a low-nanomolar IC(50) – suggesting that minimal inhibition of degradation...
Autores principales: | Pitcher, David S., de Mattos-Shipley, Kate, Tzortzis, Konstantinos, Auner, Holger W., Karadimitris, Anastasios, Kleijnen, Maurits F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534688/ https://www.ncbi.nlm.nih.gov/pubmed/26288836 http://dx.doi.org/10.1016/j.ebiom.2015.05.016 |
Ejemplares similares
-
Alterations of the Intracellular Peptidome in Response to the Proteasome Inhibitor Bortezomib
por: Gelman, Julia S., et al.
Publicado: (2013) -
The resistance mechanisms of proteasome inhibitor bortezomib
por: Lü, Shuqing, et al.
Publicado: (2013) -
Combined Inhibition of p97 and the Proteasome Causes Lethal Disruption of the Secretory Apparatus in Multiple Myeloma Cells
por: Auner, Holger W., et al.
Publicado: (2013) -
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
por: Boccadoro, Mario, et al.
Publicado: (2005) -
Proteasome Inhibitor Bortezomib Ameliorates Intestinal Injury in Mice
por: Yanaba, Koichi, et al.
Publicado: (2012)